Science Advisory Board

 

Dr. Jay Short

Dr. Short was a founder of Diversa Corporation (NASDAQ: DVSA) where, over his 11 year tenure, he served in multiple roles including CEO, President, Chief Technology Officer, and Director. Dr. Short led the company’s highly successful initial public offering, which raised over $200 million in gross proceeds – the largest biotechnology IPO ever completed at the time. During his tenure as CEO, his team also raised $300 million in committed funding from corporate partners that included Novartis, Syngenta, Dow, Merck, Dupont, Givaudan, and Cargill. Diversa utilizes genomic technologies for discovery and optimization of novel products from genes derived from microbial diversity for industrial, chemical, agricultural and pharmaceutical applications. The company has been recognized as a member of the Deloitte and Touche’s Orange County / San Diego Technology “Fast 50’ for each year following its IPO. Before joining Diversa Corporation, Dr. Short served as President of Stratacyte, Inc. and Vice President of Research & Development and Operations for Stratagene Cloning Systems, a molecular biology company based in La Jolla, California. Dr. Short earned his Ph.D. in Biochemistry at Case Western Reserve University and his BA in chemistry with honors at Taylor University. Dr. Short received San Diego's 2001 Ernst & Young Entrepreneur of the Year Award in Health Sciences and was the recipient of two first place awards granted by the University of California, San Diego, Connect Program.

In addition, Dr. Short's grant program was selected as one of the top one percent of research programs in the United States for commercializing new products funded by the SBIR program. He has authored more than 100 publications and is named inventor of over 100 issued patents and several hundred pending patents. His patents were cited by MIT Magazine as being in the top 10 in the world both in 2003 and 2004 across all industries based on citation frequency. He has served on the U.S. National Research Council panel for Chemical Science and Technology at the National Institute of Standards and Technology and numerous other governmental, grant and journal review committees and boards.

In 2003 he received the ABL Innovations in HealthCare Gold award and in 2004 he received the Henry F. Whalen, Jr. Award for Business Development by the American Chemical Society. Dr. Short currently serves as a Director for Invitrogen, (NASDAQ: IVGN) Carlsbad, California, a leading biotechnology company in the area of gene expression, Senomyx (NASDAQ: SNMX), a leader in using biotechnology for the development of novel food and beverage ingredients, Nventa (TORONTO: NVN), a pioneering immune therapeutics company and Anaptys, an protein therapeutics company. He is an advisor for City National Bank and the Biotechnology Investment Group. In addition, he is a lifetime fellow of the Explorer’s Club, member of YPO and, most recently, both founder and co-owner of Capia IP, LLC, a strategic intellectual property company and BioAtla, a global protein evolution and engineering services company based in San Diego and Beijing.

Dr. Short is currently the Chairman, CEO & Principal of BioAtla, a global, protein engineering and evolution company.

He also currently serves on the Boards of Directors of Invitrogen, a biotechnology company in the area of gene expression, Senomyx, a leader in using biotechnology for the development of novel food and beverage ingredients; Anaptys, a second-generation therapeutic antibody company; and is Entrepreneur in Residence for UCSD-Connect. Dr. Short joined the Neurorepair SAB in March, 2007.

Back to Management Team

Back to top

 

 

Dr. Jay Short
Dr. Jay Short